Press Releases
Hyperion Therapeutics to Present at Needham Healthcare Conference
South San Francisco, California - June 4, 2010Hyperion Therapeutics, Inc. today announced that Donald Santel, Chief Executive Officer, will present at the Needham Healthcare Conference on Wednesday June 9, 2010 at 10:20 am Eastern Time. The conference will be held at the New York Palace Hotel in New York City.
About Hyperion Therapeutics
Hyperion Therapeutics is a privately held pharmaceutical company focused on the development of therapies that address critical unmet needs and underserved patient populations in the areas of gastroenterology and hepatology. Hyperion and Ucyclyd Pharma, Inc., a subsidiary of Medicis Pharmaceutical Corporation, entered into a collaboration agreement for HPN-100 (glycerol phenylbutyrate) in August 2007. Under the terms of the agreement, Hyperion is conducting ongoing research and development of HPN-100 for urea cycle disorders, hepatic encephalopathy, and other forms of hyperammonemia. Hyperion is headquartered in South San Francisco, CA. For additional information, visit www.hyperiontx.com .
Press contact:
Jeff Farrow
Hyperion Therapeutics, Inc.
650-745-7816